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What is the best macrolide 
for atypical pneumonia?
■ EVIDENCE-BASED ANSWER
Erythromycin, clarithromycin, and azithromycin
are equally effective in treating pneumonia
caused by Mycoplasma pneumoniae or
Chlamydophila (formerly Chlamydia) pneumoniae
(strength of recommendation [SOR]: B, small
head-to-head trials). Macrolide choice can be
based on other considerations—cost, side effects,
and effectiveness against other suspected
pathogens (SOR: C, expert opinion).
■ EVIDENCE SUMMARY
M pneumoniae and C pneumoniae account for about
30% of community-acquired pneumonia (CAP),
making them the most common “atypicals.”
Clinically they are indistinguishable from other
causes of pneumonia; most studies use cultures to
identify cases among populations with CAP. 
Azithromycin and erythromycin were compared
in 3 studies of children with CAP.1–3 Together, they
identified 69 cases due to M pneumoniae or C pneu-
moniae. Only 3 patients did not respond to either
antibiotic. In the largest of the 3 studies,3 side
effects were noted in 10% of CAP patients on
azithromycin and 20% on erythromycin (P<.05). 
Another study looked at patients aged 12 to 80
years with pneumonia due to M pneumoniae
(75 cases) or Chlamydophila psittaci (formerly
Chlamydia psittaci, 16 cases).4 All patients
responded to treatment. Clarithromycin and eryth-
romycin were compared in children aged 3 to 12
years with CAP.5 M pneumoniae or C pneumoniae
was identified in 42 cases. Two of 18 patients did
not respond to erythromycin; 3 of 27 patients did
not respond to clarithromycin. 
Another study compared these antibiotics for
patients with CAP aged 12 to 93 years.6 Subgroup
analysis of those with M pneumoniae or C pneumo-
niae (n=27) showed similar efficacy. Pooling all
268 patients with CAP, side effects were seen in
31% of patients on clarithromycin and 59% on
erythromycin (P<.001).
A comparison study of newer macrolides in 40
adults with CAP identified 13 with M pneumoniae
or C pneumoniae (Table).7 One patient did not
respond of the 8 treated with clarithromycin; none
among the 5 treated with azithromycin. There was
1 adverse event (from clarithromycin).
■ RECOMMENDATIONS FROM OTHERS
The Infectious Diseases Society of America8 rec-
ommends a macrolide for adults with pneumonia
caused by M pneumoniae or C pneumoniae, and does
not promote one over another. The British Thoracic
Society9 recommends any of the macrolides for
pneumonia caused by these pathogens in children.
Since CAP is often caused by “atypical organ-
isms,” macrolides are sometimes recommended
as empiric outpatient therapy. In this setting, the
American Thoracic Society10 discourages using
erythromycin, citing a higher side-effect rate and
poorer effectiveness against Haemophilus influen-
za. However, the Canadian Infectious Disease
Society11 supports the use of any of the 3
macrolides in mild CAP except for patients with
chronic obstructive pulmonary disease, who are
more likely to harbor H influenza. 
Jon O. Neher, MD, Valley Medical Center Family Medicine
Residency, Renton, Wash; Jacqueline R. Morton, MLIS,
Group Health Cooperative, Seattle, Wash
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Does warfarin prevent 
deep venous thrombosis 
in high-risk patients?
■ EVIDENCE-BASED ANSWER
Warfarin (Coumadin) is effective in preventing
deep venous thrombosis (DVT) among patients
with a  history of DVT. Conventional dosing and
longer durations are the most effective, but the
ideal length of therapy is unknown (strength of
recommendation [SOR]: A, based on large ran-
domized controlled trials and meta-analysis). 
Warfarin is useful in preventing DVT in patients
with cancer, specifically those treated with chemo-
therapy (SOR: B, based on small randomized 
Macrolides: comparison studies
Cost for course of
Antibiotic Response rates* (%) Side-effect rates† (%) therapy in adult‡
Erythromycin1–4 77–100 10–59 $11 (500 mg #40)
Clarithromycin5–7 88–94 5–31 $76 (250 mg #20)
Azithromycin1–4,7 87–100 0–14 $57 (250 mg #6)
*Response rates of pneumonia due to M pneumoniae and C pneumoniae.
† In community-acquired pneumonia treated with macrolide as single agent.
‡ Prices from www.drugstore.com.
TA B L E   
■ CLINICAL COMMENTARY
Lower respiratory infections—
a number of problematic decisions
You face several problematic decisions when
treating a patient with a lower respiratory
infection. First, is this pneumonia or just
bronchitis? Clinical findings can be confus-
ing, and a chest film is helpful.12 If pneumonia
is likely, you consider hospitalization, and
prescribe antibiotics, usually without know-
ing the pathogen.
Because they cover both typical and atypical
pathogens, macrolides (or doxycycline) are
generally recommended, with cephalosporins
to be added for higher-risk patients. (Quinolones
are an alternative to this combination.) Finally,
if you choose a macrolide, you face yet another
decision without a clear answer: which one to
use? All macrolides appear to be equally effec-
tive, so the choice depends on cost balanced
against convenience and side effects. 
David Mouw, MD, Mountain Area AHEC, Asheville, NC
